- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00768391
Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is Available
27. juni 2011 opdateret af: Eli Lilly and Company
Phase I Study of Anti-Platelet Derived Growth Factor Receptor Alpha (PDGFRa) Monoclonal Antibody IMC-3G3 in Patients With Advanced Solid Tumors Who No Longer Respond to Standard Therapy or for Whom no Standard Therapy is Available
The purpose of this study is to determine if IMC-3G3 is safe for patients, and also to determine the best dose of IMC-3G3 to give to patients.
Studieoversigt
Detaljeret beskrivelse
The purpose of this study is to establish the safety profile and maximum tolerated dose (MTD) of the anti-PDGFRα monoclonal antibody IMC-3G3 in patients with advanced solid tumors who no longer respond to standard therapy or for whom no standard therapy is available.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
20
Fase
- Fase 1
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46282
- ImClone Investigational Site
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- ImClone Investigational Site
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
- Histopathological-documented, measurable, or non measurable, advanced primary tumor or recurrent solid tumor or lymphoma unresponsive to standard therapy or for which there is no standard therapy available.
- Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2 at study entry.
- Able to provide written informed consent.
- Age 18 years or older.
- Life expectancy of > 3 months.
- Adequate hematologic function, as defined by: an absolute neutrophil count ≥ 1500/mm3; a platelet count ≥ 100,000/mm3
- Adequate hepatic function, as defined by: a total bilirubin level ≤ 1.5 x the upper limit of normal (ULN); aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤ 2.5 x the ULN or ≤ 5 x the ULN if known liver metastases
- Adequate renal function, as defined by serum creatinine level ≤ 1.5 x the ULN.
- Uses effective contraception (per the institutional standard), if procreative potential exists.
- Adequate recovery from recent surgery, chemotherapy, and radiation therapy.
- Accessible for treatment and follow-up, must be treated at the participating center.
Exclusion Criteria:
- Received chemotherapy or therapeutic radiotherapy 28 days prior to the first dose of study medication or has ongoing side effects ≥ grade 2 due to agents administered more than 28 days earlier.
- Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection requiring parenteral antibiotics; symptomatic congestive heart failure; unstable angina pectoris, angioplasty, stenting, or myocardial infarction 6 months prior to the first dose of study medication; uncontrolled hypertension; clinically significant cardiac arrhythmia including but not limited to: multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment or asymptomatic sustained ventricular tachycardia; uncontrolled diabetes; psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements
- Progressive or symptomatic brain metastases
- Has a serious or nonhealing active wound, ulcer, or bone fracture.
- Known human immunodeficiency virus positivity.
- Major surgical procedure, an open biopsy, or a significant traumatic injury 28 days prior to treatment.
- Is currently or has recently used (28 days prior to) a thrombolytic agent.
- Currently using full-dose warfarin (an exception is low-dose warfarin to maintain patency of pre-existing, permanent, indwelling intravenous [I.V.] catheters; for patients receiving warfarin, the international normalized ratio [INR] should be < 1.5). A patient requiring heparin is excluded.
- Undergoes chronic daily treatment with aspirin (> 325 mg/day) or nonsteroidal anti-inflammatory medications known to inhibit platelet function (cyclooxygenase-2 [COX-2] inhibitors are permitted).
- Has a history or clinical evidence of a deep venous or arterial thrombosis (including pulmonary embolism) 6 months prior to the first dose of study medication.
- Has proteinuria ≥ 2+ by routine urinalysis
- Pregnancy (confirmed by serum beta human chorionic gonadotropin) or lactating
- Received prior treatment with agents targeting the PDGFR ligand or receptor 6 weeks prior to the first dose of study medication.
- Received prior treatment with monoclonal antibodies 6 weeks prior to the first dose of study medication.
- Has a history of allergic reactions to monoclonal antibodies or other therapeutic proteins.
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: IMC-3G3
All patients will receive intravenous infusions of IMC-3G3, with the dose depending on which cohort they are enrolled into.
|
Intravenously, once every week for Cohorts 1 through 3 and once every other week for Cohorts 4 and 5. Starting dose will be 4mg/kg in Cohort 1, with dose doubling between cohorts.
Dose escalation of 100% (2 x previous dose) Dose escalation increment reduced to 33% (1.33 x previous dose).
Cohorts 4 and 5 will receive 15mg/kg and 20mg/kg, intravenously, once every other week.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Summary of Participants Reporting Adverse Events
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
|
Maximum Tolerated Dose (MTD)
Tidsramme: Approximately 36 months
|
After all patients complete a cohort, toxicity data is reviewed before the next cohort of patients is treated at the next higher dose level
|
Approximately 36 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Farmakokinetik
Tidsramme: 6 uger
|
6 uger
|
Anti-IMC-3G3 Antibody Assessment
Tidsramme: Approximately 36 months
|
Approximately 36 months
|
Antitumor Activity of IMC-3G3 as Monotherapy
Tidsramme: 6 weeks
|
6 weeks
|
Pharmacodynamics
Tidsramme: 6 weeks
|
6 weeks
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Studieleder: E-mail: ClinicalTrials@ ImClone.com, Eli Lilly and Company
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. december 2006
Primær færdiggørelse (Faktiske)
1. marts 2009
Studieafslutning (Faktiske)
1. januar 2010
Datoer for studieregistrering
Først indsendt
6. oktober 2008
Først indsendt, der opfyldte QC-kriterier
7. oktober 2008
Først opslået (Skøn)
8. oktober 2008
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
28. juni 2011
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
27. juni 2011
Sidst verificeret
1. juni 2011
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 13937
- CP15-0601 (Anden identifikator: ImClone, LLC)
- I5B-IE-JGDC (Anden identifikator: Eli Lilly and Company)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
produkt fremstillet i og eksporteret fra U.S.A.
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Faste tumorer
-
Memorial Sloan Kettering Cancer CenterRekrutteringSolid tumor | Solid tumor, voksen | Solid tumor, uspecificeret, voksenForenede Stater
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRekrutteringSolid tumor | Solid tumor, voksen | Solid tumor, uspecificeret, voksenForenede Stater, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRekrutteringSolid tumor | Solid tumor, voksen | Solid tumor, uspecificeret, voksenForenede Stater, Puerto Rico
-
Sorrento Therapeutics, Inc.Trukket tilbageSolid tumor | Recidiverende solid tumor | Refraktær tumor
-
BeiGeneRekrutteringSolid tumor | Avanceret solid tumorForenede Stater, New Zealand, Australien, Kina
-
Anjali PawarRekrutteringSolid tumor | Solid tumor, barndomForenede Stater
-
Impact Therapeutics, Inc.RekrutteringSolid tumor | Avanceret solid tumorKina, Taiwan, Forenede Stater, Australien
-
Partner Therapeutics, Inc.Trukket tilbageSolid tumor | Solid tumor, voksenForenede Stater
-
Novartis PharmaceuticalsAfsluttetKræft | Solid tumor | Avanceret solid tumorJapan
-
Pyxis Oncology, IncRekrutteringSolid tumor | Avanceret solid tumorForenede Stater, Spanien, Belgien
Kliniske forsøg med IMC-3G3
-
Eli Lilly and CompanyAfsluttetGastrointestinal stromal tumor (GIST)Forenede Stater, Belgien, Tyskland, Holland, Polen, Spanien
-
Eli Lilly and CompanyAfsluttetMetastase | MalignitetJapan
-
Sidney Kimmel Comprehensive Cancer Center at Johns...National Cancer Institute (NCI); Eli Lilly and CompanyAfsluttetVoksen Glioblastoma MultiformeForenede Stater
-
Eli Lilly and CompanyAfsluttetSarkom, blødt vævForenede Stater
-
Eli Lilly and CompanyAfsluttet
-
Aronora, Inc.Afsluttet
-
OHSU Knight Cancer InstituteNational Heart, Lung, and Blood Institute (NHLBI); Oregon Health and Science...AfsluttetOndartet fast neoplasma | Lymfom | PlasmacellemyelomForenede Stater
-
Aronora, Inc.AfsluttetTrombose | Slutstadie nyresygdomForenede Stater
-
Eli Lilly and CompanyAfsluttetIkke-småcellet lungekræftForenede Stater, Canada
-
Eli Lilly and CompanyAfsluttet